Establish a large-scale lung cancer genomic screening platform in the Asia-Pacific region and promote precision medicine for lung cancer
/EIN News/ — TOKYO, Dec. Feb. 21, 2022 (GLOBE NEWSWIRE) — Asia Precision Medicine Co., Ltd. (“PREMIA”) and the National Cancer Center Hospital East (“NCCHE”) announced the launch of the Lung Cancer Genomic Screening Project for Individualized Medicine in Asia-Pacific (LC-SCRUM-AP), a screening platform Genomics, which will be integrated with LC-SCRUM-Asia to create a large-scale international clinicopathologic lung cancer genomics database for the region.
Strong points
- LC-SCRUM-AP is a genomic screening platform for patients with advanced or recurrent non-small cell lung cancer.
- The goal is to further develop precision medicine in Asia by establishing a genomic screening infrastructure for the Asia-Pacific region.
- The integration of LC-SCRUM-Asia and LC-SCRUM-AP databases will create a large-scale international cancer database for lung clinics and contribute to the development of precision medicine in Asia.
PREMIA, with the cooperation of NCCHE, initiated LC-SCRUM-AP by forming an academic collaboration with sites in various countries in the Asia-Pacific region. Building on NCCHE-led LC-SCRUM-Asia*1, PREMIA aims to establish a genomic screening platform in the Asia-Pacific region and develop precision medicines for lung cancer patients not at risk. advanced or recurrent small cells.
Background
Recent advances in genomic analysis technologies, such as next-generation sequencing (NGS), have led to the development of precision medicine, in which effective and personalized cancer treatments are developed based on the results of a genomic analysis of each cancer patient. In lung cancer, many drugs targeting alterations in EGFR, ALK, ROS1, BRAF, NTRK, MET, RET and KRAS have been approved in Japan so far, only some of which are approved or available in the countries. from Asia-Pacific. In the future, precision medicine in lung cancer is expected to accelerate, with the active development of therapies targeting other genomic alterations such as HER2 exon 20 and EGFR insertion. However, the frequency of each of these genomic alterations is rare, accounting for only 1-3% of non-small cell lung cancers, excluding EGFR genomic mutations. Accordingly, the establishment of an international large-scale genomic screening platform with the cooperation of Japan and other countries through academic collaboration is essential.
With the launch of LC-SCRUM-AP, approximately 20 institutions in Thailand, Malaysia, Vietnam, Singapore, Indonesia, Australia and Taiwan will participate through academic collaboration. In cooperation with the NCCHE, PREMIA is mainly responsible for the launch of the participating sites and the development and implementation of the genomic screening platform in the Asia-Pacific region.
Clinical development based on LC-SCRUM-Asia/AP and
Creation of an international clinico-genomic database on lung cancer
The establishment of a lung cancer screening infrastructure in the Asia-Pacific region will enable larger-scale genomic screening and accelerate the development of novel molecular targeting agents for various genomic alterations. In addition, by integrating the LC-SCRUM-Asia and LC-SCRUM-AP databases and creating a clinico-genomic database for the Asia-Pacific region, large-scale real-world data will be accumulated, which should help significantly to the development of precision medicine in the Asia-Pacific region. With the cooperation of PREMIA and organizations from other countries in the region, LC-SCRUM-AP will work to further promote the development of precision medicine in Asia-Pacific.
LC-SCRUM-Asia
LC-SCRUM-Japan, a genomic screening platform launched by the National Cancer Center in 2013, in collaboration with medical institutions and pharmaceutical companies (Representative: Koichi Goto, Head of Thoracic Oncology Department, NCCHE), expanded to include East Asia in 2019 Since then it has been operating as “LC-SCRUM-Asia”, an international genomic screening project in which over 17,000 lung cancer patients participated as of September 2022 , and during which large-scale genomic analyzes were conducted. With the aim of developing new therapeutic and diagnostic agents for lung cancer. Going forward, academia and industry will continue to work together to promote the development of new therapies and diagnostics for the optimal medical treatment of lung cancer.
For more information on LC-SCRUM-Asia, visit: http://www.scrum-japan.ncc.go.jp/lc_scrum/index.html.
About Precision Medicine Asia (PREMIA)
PREMIA offers an integrated platform for the development of innovative oncology therapies and diagnostics in Asia, the fastest growing market for the pharmaceutical industry. PREMIA also maintains Japan’s national clinical genomic lung cancer registry, LC-SCRUM-Asia, the only such database in Asia. The registry currently includes more than 17,000 patients and enables an efficient patient identification process for clinical trial enrollment through the participation of more than 200 hospitals in Japan and Taiwan, with the addition of hospitals in Asia du Sud-Est via LC-SCRUM-AP starting in 2022. For more information, please visit www.premia-inc.com.
About the National Cancer Center Hospital East (NCCHE)
The National Cancer Center Hospital East (NCCHE) was established in 1992. It is a leading cancer specialty hospital in Japan, treating more than 9,000 new patients each year. The NCCHE is designated by the national government as a referral hospital for clinical research and a referral hospital for cancer genomics treatment, among others. Together with its adjacent facility, Center for Exploratory Research in Oncology and Clinical Trials (NCC-EPOC), NCC Hospital East has produced many achievements as a research and development center with its strong international network. The NCCHE promotes the development of innovative cancer drugs and medical devices and cutting-edge personalized treatments, including genomic medicine.
Contact details for inquiries:
Precision medicine Asia
Viviane Liu
Director, Corporate Operations
Tel: 852-3978-2288
vliu@premia-inc.com
A photo accompanying this ad is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/8e5df794-8e15-4499-8c35-050b805b7e76
Clinical development based on LC-SCRUM-Asia/AP and establishment of an international clinico-genomic database for lung cancer
Clinical development based on LC-SCRUM-Asia/AP and establishment of an international clinico-genomic database for lung cancer
0 Comments